全文获取类型
收费全文 | 6500篇 |
免费 | 543篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 134篇 |
妇产科学 | 94篇 |
基础医学 | 974篇 |
口腔科学 | 89篇 |
临床医学 | 773篇 |
内科学 | 1497篇 |
皮肤病学 | 89篇 |
神经病学 | 620篇 |
特种医学 | 205篇 |
外科学 | 775篇 |
综合类 | 109篇 |
一般理论 | 6篇 |
预防医学 | 621篇 |
眼科学 | 99篇 |
药学 | 558篇 |
中国医学 | 10篇 |
肿瘤学 | 356篇 |
出版年
2023年 | 30篇 |
2022年 | 59篇 |
2021年 | 161篇 |
2020年 | 105篇 |
2019年 | 146篇 |
2018年 | 159篇 |
2017年 | 121篇 |
2016年 | 148篇 |
2015年 | 166篇 |
2014年 | 211篇 |
2013年 | 296篇 |
2012年 | 488篇 |
2011年 | 456篇 |
2010年 | 255篇 |
2009年 | 228篇 |
2008年 | 375篇 |
2007年 | 363篇 |
2006年 | 363篇 |
2005年 | 413篇 |
2004年 | 371篇 |
2003年 | 344篇 |
2002年 | 310篇 |
2001年 | 127篇 |
2000年 | 126篇 |
1999年 | 99篇 |
1998年 | 61篇 |
1997年 | 44篇 |
1996年 | 47篇 |
1995年 | 49篇 |
1994年 | 40篇 |
1993年 | 38篇 |
1992年 | 76篇 |
1991年 | 64篇 |
1990年 | 66篇 |
1989年 | 64篇 |
1988年 | 59篇 |
1987年 | 55篇 |
1986年 | 50篇 |
1985年 | 47篇 |
1984年 | 36篇 |
1983年 | 27篇 |
1982年 | 17篇 |
1980年 | 16篇 |
1979年 | 24篇 |
1978年 | 20篇 |
1977年 | 19篇 |
1974年 | 16篇 |
1973年 | 21篇 |
1972年 | 23篇 |
1967年 | 14篇 |
排序方式: 共有7057条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
5.
6.
Mhd Wasem Alsabbagh Dana Church Lisa Wenger John Papastergiou Lalitha Raman-Wilms Eric Schneider Nancy Waite 《Research in social & administrative pharmacy》2019,15(2):202-206
Background
One approach to boost influenza vaccination coverage has been to expand immunization authority. In 2012, the province of Ontario gave community pharmacists the authority to administer the influenza vaccine.Objective
This study investigates the perspectives of Ontario pharmacy patrons, who had not recently received this vaccine from a pharmacist, regarding this pharmacist service.Methods
A survey was administered in six Ontario community pharmacies to pharmacy patrons who had not received an influenza vaccination from a pharmacist during the previous year. The instrument included questions about influenza vaccination, and knowledge of and attitudes toward vaccines and pharmacist-administered immunization.Results
A total of 541 pharmacy patrons completed the survey (53.9% response rate). About one-third (30.5%) of respondents were not aware that pharmacists could give the influenza vaccine, with younger individuals being less likely to be aware (OR 0.48, 95% CI 0.29–0.77, p?<?0.05) and less likely to receive the vaccine annually (OR 0.28, 95% CI 0.19–0.42, p?<?0.05). Leading reasons respondents gave as to why they did not receive their influenza vaccine from a pharmacist included not wanting or feeling they needed to be immunized (41.6%) and being used to receiving the vaccine from a physician (16.5%). Concerns about the experience and training of pharmacists and lack of privacy in a community pharmacy were uncommon.Conclusion
Reduced awareness of the availability of pharmacist-provided influenza vaccine is still common. Pharmacists have a significant opportunity to address lack of awareness and vaccine hesitancy issues. They can promote this service to increase influenza vaccination rates among pharmacy patrons who do not utilize this professional service. 相似文献7.
8.
Gavin Wright 《ANZ journal of surgery》2005,75(11):952-952
9.
10.